Seamless Therapeutics announced today that it has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company (“Lilly”) to develop and commercialize programmable recombinase-based treatments targeting hearing loss indications, using Seamless’ proprietary recombinase platform.

无缝治疗公司今天宣布，已与礼来公司（“礼来”）达成一项战略性的全球研究合作和许可协议，利用无缝治疗公司的专有重组酶平台，开发和商业化针对听力损失适应症的可编程重组酶治疗方法。

The company’s technology performs large, precise DNA insertions in any target gene sequence, and operates independent of the cell’s natural DNA repair pathway..

该公司技术可在任何目标基因序列中进行大型、精确的DNA插入，并且独立于细胞的天然DNA修复途径运行。

Under the terms of the agreement, Seamless will design and program site-specific recombinases directed to correct mutations in certain genes of interest related to hearing loss. Lilly will receive an exclusive license to the programmed recombinases to advance through preclinical and clinical drug development and commercialization..

根据协议条款，Seamless 将设计和编程针对特定基因位点的重组酶，以纠正与听力损失相关的某些目标基因的突变。Lilly 将获得这些编程重组酶的独家许可，用于推进其在临床前、临床药物开发以及商业化进程。

“Lilly is invested in advancing novel treatment approaches for genetic diseases and shares our vision of bringing genetic medicines to patients who currently have limited treatment options. This collaboration is a validation of our gene editing platform and its broad disease-modifying potential,” said Albert Seymour, Ph.D., Chief Executive Officer of Seamless Therapeutics.

“Lilly致力于推进遗传性疾病的新疗法，并与我们拥有将基因药物带给目前治疗选择有限的患者的愿景一致。这次合作验证了我们的基因编辑平台及其广泛的疾病修饰潜力，”Seamless Therapeutics首席执行官Albert Seymour博士表示。

We look forward to working with our partners at Lilly in our shared goal to transform the outcome for patients with genetic hearing loss. It’s an exciting opportunity to apply our technology to bring treatments to patients with hearing loss and continue to expand the therapeutic potential for programmable recombinases through our proprietary pipeline.”.

我们期待与礼来公司的合作伙伴共同努力，实现我们共同的目标，即改变遗传性听力损失患者的治疗结果。这是一个激动人心的机会，可以应用我们的技术为听力损失患者带来治疗方法，并通过我们的专有渠道进一步拓展可编程重组酶的治疗潜力。"

As part of the agreement, Seamless receives a guaranteed upfront payment and committed research and development funding. In total, Seamless is eligible for over $1.12 billion, including potential development and commercial milestone payments, excluding tiered royalties on successfully marketed drugs.

根据协议，Seamless 将获得一笔有保证的预付款和承诺的研发资金。总计而言，Seamless 有资格获得超过 11.2 亿美元的款项，其中包括潜在的开发和商业里程碑付款，但不包括成功上市药物的阶梯式专利费。

Further details of the agreement have not been disclosed..

协议的更多细节尚未披露。

Seamless is translating major breakthroughs in programming recombinases, a class of enzymes that have been widely used in scientific research for decades, transforming their accuracy and flexibility, to enable therapeutic gene editing. The company’s unique technology platform allows for site-specific programmable recombinases that are engineered for specificity and activity in order to precisely insert, exchange, invert, or excise  DNA fragments in any target gene sequence in the genome.

Seamless公司正在转化编程重组酶的重大突破，这类酶几十年来一直广泛应用于科学研究，通过提高其准确性和灵活性，实现治疗性基因编辑。该公司独特的技术平台能够设计出针对特定位置的可编程重组酶，这些重组酶经过工程改造以具备特异性和活性，从而能够在基因组中的任何目标基因序列上精确插入、交换、倒置或切除DNA片段。

By advancing Seamless’ novel programmable recombinases, this agreement opens the potential for the technology to address a high unmet need in genetic hearing loss..

通过推进Seamless的新型可编程重组酶，该协议开启了这项技术在遗传性听力损失方面的高未满足需求的潜力。

About Seamless Therapeutics

关于Seamless Therapeutics

Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach that has the potential to address unmet medical needs in patients who suffer from severe conditions. Our technology platform unlocks the programming of recombinases, a highly versatile class of enzymes. We are applying our proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing..

Seamless Therapeutics 正在通过一种开创性的方法改变基因编辑的范式，这种方法有潜力满足遭受严重疾病困扰患者的未竟医疗需求。我们的技术平台解锁了重组酶的编程能力，这是一类功能极为多样的酶。我们正在运用专有的技术知识，开发覆盖广泛适应症的疾病修饰产品候选管线，以拓展基因编辑的治疗潜力。

For more information, please contact:

更多信息，请联系：

Seamless Therapeutics

无缝治疗学

Albert Seymour, CEO

阿尔伯特·塞缪尔，首席执行官

Email: info@seamlesstx.com

电子邮件：info@seamlesstx.com

Seamless Therapeutics media inquiries

无缝治疗媒体咨询

Trophic Communications

营养通讯

Stephanie May and Eva Mulder

史蒂芬妮·梅和伊娃·穆尔德

Tel: +49 171 1855682 or +31 6 52 33 15 79

电话：+49 171 1855682 或 +31 6 52 33 15 79

Email: seamless@trophic.eu

电子邮件：seamless@trophic.eu

Source: globenewswire.com

来源：globenewswire.com